# Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia

> **NCT00021151** · NA · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 2 (actual)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** alemtuzumab

## Key facts

- **NCT ID:** NCT00021151
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01
- **Primary completion:** 2001-04
- **Final completion:** 2002-05
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2014-01-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00021151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00021151, "Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00021151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*